Search results for "PULMONARY"

showing 10 items of 3030 documents

Les Junipereta macrocarpae sur sable

1990

espanolLos autores estudian lalunipereta macrocarpae sobre arena de dunas mediterraneas. La aplicacion de metodos fitosociologicos actuales permiten distinguir sobre las costas mediterraneas y los litorales vecinos cuatro asociaciones territoriales geosinvicariantes con Junipertis avycedrus L. subsp. macrocarpa (Sibth. et Sm.) Ball teniendo cada una un entorno geografico particular. francaisLes auteurs etudient les Junipereta macrocarpae sur sable des dunes mediterraneennes. L'application des methodes phytosociologiques actuelles permet de mettre en evidence sur les dotes mediterraneennes et les littoraux voisins quatre associations territoriales geosynvicariantes a Juniperus oxycedrus L. s…

Pulmonary and Respiratory MedicinePediatrics Perinatology and Child HealthActa Botanica Malacitana
researchProduct

Length of remdesivir treatment in patients with severe COVID-19

2021

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has caused more than 96 million cases and over 2 million deaths worldwide as of January 21, 2021. As the crisis continues, the scientific community, institutions and pharmaceutical industries are striving to find effective therapies to prevent or treat the disease. Remdesivir (GS-5734) was early identified as an option.

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)RC705-779Journal Clubbusiness.industry4Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RemdesivirMEDLINEExpert Opinion03 medical and health sciencesRegimenDiseases of the respiratory system0302 clinical medicine030228 respiratory systemSAFERMedicineIn patient030212 general & internal medicinebusinessBit (key)Breathe
researchProduct

Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D'Amato et al

2021

We have read with interest the letter from D’Amato et al. entitled “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations”....

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)business.industryHome therapySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19030204 cardiovascular system & hematologyLMWH03 medical and health sciences0302 clinical medicinemedicineSteroidsbusinessLetter to the EditorHome therapy030215 immunology
researchProduct

An Official American Thoracic Society Workshop Report: Evaluation and Management of Asthma in the Elderly.

2016

Asthma in the elderly (>65 yr old) is common and associated with higher morbidity and mortality than asthma in younger patients. The poor outcomes in this group are due, in part, to underdiagnosis and undertreatment. There are a variety of factors related to aging itself that affect the presentation of asthma in the elderly and influence diagnosis and management. Structural changes in the aging lung superimposed on structural changes due to asthma itself can worsen the disease and physiologic function. Changes in the aging immune system influence the cellular composition and function in asthmatic airways. These processes and differences from younger individuals with asthma are not well u…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAgingImmunosenescenceaging; immunosenescence; lung function; phenotype; reactive airways diseaseDiseaseComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)Diagnosis Differential03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineimmune system diseasesreactive airways diseasemedicineHumans030212 general & internal medicineDisease management (health)LungSocieties MedicalAsthmaAgedAmerican Thoracic Society DocumentsLungbusiness.industryDisease Managementlung functionImmunosenescencemedicine.diseaseComorbidityAsthmaUnited Statesrespiratory tract diseasesmedicine.anatomical_structurePhenotype030228 respiratory systemPhysical therapyAge of onsetbusinessBiomarkersAnnals of the American Thoracic Society
researchProduct

Should atopy be assessed in elderly patients with respiratory symptoms suggestive of asthma?

2010

Aging is associated with modifications of the immune system and this could contribute to a reduced prevalence of allergic disease in the elderly. Atopy has rarely been considered in the clinical assessment of the geriatric respiratory patient. This article is a review of the available literature assessing the impact of age on atopy in the asthmatic patient. In the majority of papers, we found a lower prevalence of atopy in the most advanced ages, both in healthy subjects and in individuals affected by allergic respiratory diseases. No large, longitudinal studies performed in the general population have been conducted to confirm this observation. Although available data seem to favor the dec…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAgingPopulationDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin Emedicine.disease_causeAtopyAllergic sensitizationAllergenmedicineHypersensitivityPrevalenceImmunology and AllergyHumansaging allergy asthmaRespiratory systemeducationAsthmaAgedAged 80 and overeducation.field_of_studybiologybusiness.industryPublic Health Environmental and Occupational HealthAge FactorsAllergensmedicine.diseasePrognosisAsthmaImmunologybiology.proteinbusinessExpert review of respiratory medicine
researchProduct

Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe.

2017

While there is evidence for variations in prevalence rates of childhood wheeze and asthma between countries, longitudinal, individual-level data are needed to understand these differences. The aim of this study was to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe. We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts in eight countries, representing 26 663 children, to calculate prevalence rates of wheeze and asthma by child age and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze and parent-reported doctor-diagnosed asthma, and covariates maternal education…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergy5Child age12Prevalencelcsh:MedicineChildhood asthma03 medical and health sciences0302 clinical medicineimmune system diseasesWheezeJournal Articlemedicine030212 general & internal medicineSleep medicineAsthmaChildhood asthmaAsthma and allergybusiness.industrylcsh:ROriginal Articlesmedicine.disease3. Good healthrespiratory tract diseasesMaternal educationCOPD and smoking030228 respiratory systemmedicine.symptombusinessDemography
researchProduct

Allergic diseases of the skin and drug allergies – 2015. Randomized controlled, double blind trial of topical twice weekly fluticasone propionate mai…

2013

Allergic diseases of the skin and drug allergies – 2015. Randomized controlled, double blind trial of topical twice weekly fluticasone propionate maintenance treatment to reduce risk of relapse in mild or moderate atopic dermatitis in children Elena Rubio, Inocencia Martinez-Mir, Francisco J Morales-Olivas, Antonio Martorell-Aragones, Vicente Palop Larrea, Alejandro Bernalte Sese, Juan C Cerda Mir, Pedro Polo Martin, Isabel Febrer, Laura Aranda Grau, Inmaculada Llosa Cortes, Maria Jose Tejedor Sanz, Juan C Julia Benito, Teresa Alvarez De Laviada, Maria Victoria Planelles Cantarino, Esther Apolinar Valiente, Mercedes Loriente Tur, Antonio M Abella Bazataqui, Irene Alvarez Gonzalez, Cristina …

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAllergybusiness.industryImmunologyAtopic dermatitismedicine.diseaseFluticasone propionateDouble blindMeeting AbstractmedicineImmunology and AllergyRelapse riskbusinessmedicine.drugFluticasoneThe World Allergy Organization Journal
researchProduct

P141 2-year follow-up of COPD patients in the non-interventional ‘real-life’ daccord study in germany

2016

Introduction Although randomised, controlled trials are important in the development of new pharmacological treatments, they provide limited information on the ‘real life’ management of chronic diseases. Here, we analysed two-year follow-up data from the prospective, non-interventional, observational DACCORD study to evaluate the frequency of exacerbations and the evolution of disease severity using GOLD 2011 categorization. Methods COPD out-patients were recruited into DACCORD following either a change or initiation of COPD maintenance medication and followed up for 2 years. Data of 3137 patients that completed the 2-year follow-up were analysed; Exacerbation data were collected from the 6…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCOPDExacerbationbusiness.industryCopd patientsmedicine.diseaseLower riskCohortNon interventionalmedicineObservational studybusinessProgressive diseaseThorax
researchProduct

P46 Frequency of COPD exacerbations in the German DACCORD Registry

2015

Introduction In patients with COPD, exacerbations are among the most relevant safety measures. In this analysis of data from the observational DACCORD study, we report the frequency of exacerbations in a COPD population. Methods To get insights into occurrence and frequency of exacerbations, data from 4,123 patients were obtained from 349 primary and secondary care centres in Germany. To be eligible for entry into DACCORD, all patients had to have a COPD diagnosis (consistent with the German Disease Management Programme definition), and had to have a change in bronchodilator maintenance medication, prior to entry. Data collected included history and treatment of exacerbations 6 months prior…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCOPDeducation.field_of_studyExacerbationbusiness.industrymedicine.drug_classPopulationDiseasemedicine.diseaseBronchodilatorCohortMedicineObservational studyMedical prescriptionbusinesseducationThorax
researchProduct

Efficacy and effectiveness of omalizumab in the treatment of childhood asthma

2018

Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E, a mediator involved in the clinical manifestations of allergic asthma. Evidence for its efficacy and safety in the treatment of moderate-to-severe allergic asthma is based primarily on studies in adolescents and adults. However, there is increasing evidence of its utility in children with allergic asthma aged 6-12 years. Areas covered: This article reviews efficacy, safety, and effectiveness of omalizumab in the treatment of moderate-to-severe allergic asthma in children aged 6-12 years in clinical trials and in studies in clinical practice. Pharmacoeconomic aspects of its use among this population and …

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyCost-Benefit AnalysisPopulationOmalizumabOmalizumabImmunoglobulin E03 medical and health sciences0302 clinical medicineimmune system diseasesmedicineHumansImmunology and AllergyAnti-Asthmatic Agents030212 general & internal medicineChildeducationPediatric asthmaAsthmaChildhood asthmaeducation.field_of_studybiologybusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseaseAsthmarespiratory tract diseasesClinical PracticeClinical trial030228 respiratory systembiology.proteinbusinessmedicine.drugExpert Review of Respiratory Medicine
researchProduct